| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ART.21918 |
| P698 | PubMed publication ID | 16729277 |
| P50 | author | Roberto Civitelli | Q38323326 |
| Penelope Ward | Q56461749 | ||
| P2093 | author name string | Robert R Recker | |
| David M Reid | |||
| Claus Christiansen | |||
| Claire Hughes | |||
| Jean-Yves Reginster | |||
| Dieter Felsenberg | |||
| Pierre D Delmas | |||
| Silvano Adami | |||
| Philip Sambrook | |||
| Jacob A Stakkestad | |||
| Marc K Drezner | |||
| Michael Bolognese | |||
| Daiva Masanauskaite | |||
| Cezary Strugala | |||
| P433 | issue | 6 | |
| P921 | main subject | osteoporosis | Q165328 |
| immunology | Q101929 | ||
| rheumatology | Q327657 | ||
| P304 | page(s) | 1838-1846 | |
| P577 | publication date | 2006-06-01 | |
| P1433 | published in | Arthritis and Rheumatism | Q23929027 |
| P1476 | title | Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study | |
| P478 | volume | 54 |
| Q36739641 | A systematic review of persistence and compliance with bisphosphonates for osteoporosis |
| Q37246255 | Adverse effects of bisphosphonates: implications for osteoporosis management |
| Q34189582 | Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis |
| Q27013070 | An overview on the treatment of postmenopausal osteoporosis |
| Q34225188 | Basic and clinical aspects of osteoporosis in inflammatory bowel disease. |
| Q38034435 | Biomarkers of bone turnover in diagnosis and therapy of osteoporosis: a consensus advice from an Austrian working group |
| Q37237318 | Bisphosphonate nephrotoxicity |
| Q58971260 | Bisphosphonates |
| Q36443681 | Bisphosphonates for the treatment of osteoporosis: insights for clinicians |
| Q36897441 | Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice |
| Q35954529 | Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate |
| Q36897449 | Clinical challenges in the management of osteoporosis |
| Q36162247 | Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis |
| Q47117629 | Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology |
| Q38294766 | Considerations regarding adherence of anti-osteoporosis therapy. |
| Q37931985 | Current options for the management of postmenopausal osteoporosis |
| Q37826521 | Defining treatment failure in severe osteoporosis |
| Q34042003 | Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis |
| Q37199923 | Diagnosis and management of osteoporosis in the older senior |
| Q35858255 | Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis: A Meta-Analysis |
| Q41091281 | Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study |
| Q36979311 | Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate |
| Q35644131 | Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet |
| Q33965657 | Efficacy of ibandronate: a long term confirmation. |
| Q84174634 | Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates |
| Q36944034 | Emerging pharmacologic therapies for osteoporosis |
| Q24612411 | European guidance for the diagnosis and management of osteoporosis in postmenopausal women |
| Q37037296 | European guidance for the diagnosis and management of osteoporosis in postmenopausal women |
| Q57465255 | European guidance for the diagnosis and management of osteoporosis in postmenopausal women |
| Q36056975 | Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review |
| Q34099162 | Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club |
| Q47417160 | Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate |
| Q53559191 | Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study. |
| Q42970094 | Ibandronate and nonvertebral fracture efficacy: results of a recent pooled analysis |
| Q82367199 | Ibandronate for prevention and treatment of glucocorticoid-induced osteoporosis in rabbits |
| Q31165701 | Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data |
| Q38750001 | Ibandronate: A Review in Japanese Patients with Osteoporosis |
| Q37354137 | Ibandronate: a review of its use in the management of postmenopausal osteoporosis |
| Q36792733 | Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women |
| Q43255253 | Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study |
| Q43267037 | Injectable bisphosphonates for the treatment of osteoporosis |
| Q36822375 | Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date |
| Q34863964 | Intravenous bisphosphonates for postmenopausal osteoporosis |
| Q34645740 | Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice |
| Q51487384 | Intravenous ibandronate acutely reduces bone hyperresorption in chronic critical illness. |
| Q79416557 | Intravenous ibandronate in the treatment of osteoporosis: profile report |
| Q36586906 | Intravenous ibandronate: in the treatment of osteoporosis |
| Q34041189 | Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension |
| Q34758140 | Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis |
| Q44468289 | Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies |
| Q34018048 | Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis |
| Q37287270 | Management of osteoporosis among home health and long-term care patients with a prior fracture |
| Q37823835 | Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. |
| Q82331363 | New Approaches to the Treatment of Osteoporosis |
| Q37254577 | Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates |
| Q34272000 | Once-monthly risedronate for postmenopausal osteoporosis |
| Q37192994 | Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations |
| Q24670075 | Osteoporosis and its management |
| Q38104738 | Osteoporosis treatment: why ibandronic acid? |
| Q46990986 | Osteoporosis: non-hormonal treatment |
| Q37781739 | Pharmacologic undertreatment of osteoporosis in Austrian nursing homes and senior's residences |
| Q35940958 | Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis |
| Q37038535 | Prevalent and Emerging Therapies for Osteoporosis |
| Q37417515 | Preventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: regimen selection and clinical application. |
| Q37346101 | Quarterly intravenous ibandronate for postmenopausal osteoporosis |
| Q37017272 | Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women |
| Q38125952 | Renal safety in patients treated with bisphosphonates for osteoporosis: a review. |
| Q36984235 | Renal safety of intravenous bisphosphonates in the treatment of osteoporosis |
| Q37725841 | Risk factors of osteonecrosis of the jaw after tooth extraction in osteoporotic patients on oral bisphosphonates |
| Q37866764 | Safety of long-term bisphosphonate therapy for the management of osteoporosis |
| Q38209896 | The association between critical illness and changes in bone turnover in adults: a systematic review |
| Q51153117 | The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis. |
| Q44892769 | The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. |
| Q38611601 | The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women |
| Q38335645 | Treatment of osteoporosis in renal insufficiency. |
| Q33482516 | Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates. |
| Q37765866 | Update on the use of zoledronic acid in the management of osteoporosis |
| Q35008617 | Updated recommendations for the diagnosis and management of osteoporosis: a local perspective |
| Q39385131 | Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability |
| Q37800181 | Use of bisphosphonates in the management of postmenopausal osteoporosis |
| Q37951107 | Use of bone turnover markers in clinical osteoporosis assessment in women: current issues and future options |
| Q61217399 | Use of intravenous bisphosphonates in osteoporosis |
| Q42171414 | Zoledronic acid reduces osteoporotic fractures and ensures medication compliance for 1 year |
| Q79657959 | [Bisphosphonates in osteoporosis therapy. Standards and perspectives] |
| Q83518547 | [Current diagnosis and therapy of osteoporosis on the basis of "European guidance 2008"] |
Search more.